0001193125-21-152385.txt : 20210506 0001193125-21-152385.hdr.sgml : 20210506 20210506060929 ACCESSION NUMBER: 0001193125-21-152385 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210505 ITEM INFORMATION: Other Events FILED AS OF DATE: 20210506 DATE AS OF CHANGE: 20210506 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Vincerx Pharma, Inc. CENTRAL INDEX KEY: 0001796129 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 833197402 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39244 FILM NUMBER: 21895579 BUSINESS ADDRESS: STREET 1: 260 SHERIDAN AVENUE STREET 2: SUITE 400 CITY: PALO ALTO STATE: CA ZIP: 94306 BUSINESS PHONE: 650-800-6676 MAIL ADDRESS: STREET 1: 260 SHERIDAN AVENUE STREET 2: SUITE 400 CITY: PALO ALTO STATE: CA ZIP: 94306 FORMER COMPANY: FORMER CONFORMED NAME: Vincera Pharma, Inc. DATE OF NAME CHANGE: 20201223 FORMER COMPANY: FORMER CONFORMED NAME: LifeSci Acquisition Corp. DATE OF NAME CHANGE: 20191206 8-K 1 d424828d8k.htm FORM 8-K Form 8-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 5, 2021

 

 

Vincerx Pharma, Inc.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-39244   83-3197402

(State or Other Jurisdiction

of Incorporation)

  

(Commission

File Number)

  

(I.R.S. Employer

Identification No.)

260 Sheridan Avenue, Suite 400   94306
Palo Alto, CA   (Zip Code)
(Address of principal executive offices)  

(650) 800-6676

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report.)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240-13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading

symbol(s)

  

Name of each exchange

on which registered

Common Stock   VINC   The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b–2 of the Securities Exchange Act of 1934 (§240.12b–2 of this chapter).

Emerging growth company  ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

 

 

 

Item 8.01

Other Events.

In connection with the previously announced call for redemption by Vincerx Pharma, Inc. (the “Company”) of its public warrants, the Company redeemed all public warrants that remained outstanding and unexercised as of close of business on May 5, 2021 for a redemption price of $0.01 per public warrant.

As of the close of business on May 5, 2021, 6,491,604 public warrants were exercised, resulting in the receipt of approximately $37.3 million in total cash proceeds, and 72,163 unexercised public warrants were redeemed at the redemption price of $0.01 per public warrant.

As of the close of business on May 5, 2021, there were 17,505,239 shares of the Company’s common stock outstanding.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: May 5, 2021

 

VINCERX PHARMA, INC.
      By:  

/s/ Raquel E. Izumi

Raquel E. Izumi
President and Chief Operations Officer